DaVita Inc. (DVA) Stock Analysis

DaVita Inc. runs kidney dialysis facilities across the United States for patients suffering from chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company operates in the healthcare sector under medical care facilities. Its core revenue comes from outpatient dialysis treatments, hospital inpatient care, and specialized clinical laboratory testing. Beyond brick-and-mortar clinics, the company provides home dialysis programs, risk-based disease management, and transplant software.

DaVita is a clear market leader operating in an entrenched duopoly alongside Fresenius Medical Care. Together, both companies control nearly 80% of all dialysis facilities in the United States, with DaVita commanding roughly 37% to 38% market share. That immense physical footprint delivers an insurmountable scale advantage over regional competitors. The primary threat to the business remains regulatory scrutiny over market concentration alongside vulnerability to government reimbursement policy shifts.

The company continues to grow at a reliable pace, booking $13.64 billion in revenue for fiscal year 2025, up 6.5% year over year. Operationally, DaVita is pivoting toward value-based care, with its Integrated Kidney Care platform hitting full-year profitability in 2025 while managing 66,000 risk-based patients. Home dialysis is also expanding rapidly as the company’s fastest-growing modality, now accounting for about 15% of patient treatments. This deliberate shift into home care and integrated management makes DaVita a far more defensive, higher-margin operator than a traditional clinic network.